Gad Singer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1480785/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma. Journal of the National Cancer Institute, 2003, 95, 484-486.	6.3	762
2	Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis. American Journal of Surgical Pathology, 2005, 29, 218-224.	3.7	388
3	Diverse Tumorigenic Pathways in Ovarian Serous Carcinoma. American Journal of Pathology, 2002, 160, 1223-1228.	3.8	320
4	The First Analysis and Clinical Evaluation of Native Breast Tissue Using Differential Phase-Contrast Mammography. Investigative Radiology, 2011, 46, 801-806.	6.2	228
5	How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS ONE, 2012, 7, e37379.	2.5	175
6	HLA-G is a potential tumor marker in malignant ascites. Clinical Cancer Research, 2003, 9, 4460-4.	7.0	141
7	HLA-G Immunoreactivity Is Specific for Intermediate Trophoblast in Gestational Trophoblastic Disease and Can Serve as a Useful Marker in Differential Diagnosis. American Journal of Surgical Pathology, 2002, 26, 914-920.	3.7	125
8	Assessment of Plasma DNA Levels, Allelic Imbalance, and CA 125 as Diagnostic Tests for Cancer. Journal of the National Cancer Institute, 2002, 94, 1697-1703.	6.3	119
9	Mutational Analysis of K-ras Segregates Ovarian Serous Carcinomas into Two Types: Invasive MPSC (Low-grade Tumor) and Conventional Serous Carcinoma (High-grade Tumor). International Journal of Gynecological Pathology, 2003, 22, 37-41.	1.4	116
10	Non-invasive classification of microcalcifications with phase-contrast X-ray mammography. Nature Communications, 2014, 5, 3797.	12.8	110
11	Epithelial growth factor receptor status in primary and recurrent ovarian cancer. Modern Pathology, 2006, 19, 607-610.	5.5	71
12	Glypican-3 Expression in Primary and Recurrent Ovarian Carcinomas. International Journal of Gynecological Pathology, 2007, 26, 341-344.	1.4	61
13	Metastatic patterns at autopsy in patients with ovarian carcinoma. Cancer, 2007, 110, 1272-1280.	4.1	61
14	Different types of microsatellite instability in ovarian carcinoma. International Journal of Cancer, 2004, 112, 643-646.	5.1	60
15	A Study on Mastectomy Samples to Evaluate Breast Imaging Quality and Potential Clinical Relevance of Differential Phase Contrast Mammography. Investigative Radiology, 2014, 49, 131-137.	6.2	57
16	Towards clinical grating-interferometry mammography. European Radiology, 2020, 30, 1419-1425.	4.5	43
17	Indeterminate adnexal masses at ultrasound: effect of MRI imaging findings on diagnostic thinking and therapeutic decisions. European Radiology, 2011, 21, 1301-1310.	4.5	35
18	Interobserver variability and likelihood of malignancy for fifth edition BI-RADS MRI descriptors in non-mass breast lesions. European Radiology, 2020, 30, 77-86.	4.5	32

GAD SINGER

#	Article	IF	CITATIONS
19	Napoleon Bonaparte's gastric cancer: a clinicopathologic approach to staging, pathogenesis, and etiology. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 52-57.	1.7	31
20	Breast Abscesses: Diagnosis, Treatment and Outcome. Breast Care, 2012, 7, 32-38.	1.4	25
21	High OX40 expression in recurrent ovarian carcinoma is indicative for response to repeated chemotherapy. BMC Cancer, 2018, 18, 425.	2.6	24
22	High IL-17-positive tumor immune cell infiltration is indicative for chemosensitivity of ovarian carcinoma. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1295-1302.	2.5	23
23	A new approach in breast cancer with non-inflammatory skin involvement. Acta Oncológica, 2006, 45, 576-583.	1.8	21
24	Transitional cell carcinoma of the vagina with pagetoid spread pattern. Human Pathology, 1998, 29, 299-301.	2.0	20
25	High density of CD66b in primary high-grade ovarian cancer independently predicts response to chemotherapy. Journal of Cancer Research and Clinical Oncology, 2020, 146, 127-136.	2.5	20
26	Breast carcinoma with noninflammatory skin involvement (T4b). Cancer, 2005, 104, 1862-1870.	4.1	19
27	T4 breast cancer under closer inspection: A case for revision of the TNM classification. Breast, 2007, 16, 625-636.	2.2	16
28	Comparison of gene expression profiles in core biopsies and corresponding surgical breast cancer samples. Breast Cancer Research, 2006, 8, R51.	5.0	15
29	Expression of peroxisome proliferator activated receptor and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma. Journal of Clinical Pathology, 2006, 60, 307-310.	2.0	15
30	Association of the Presence of Bone Marrow Micrometastases with the Sentinel Lymph Node Status in 410 Early Stage Breast Cancer Patients: Results of the Swiss Multicenter Study. Annals of Surgical Oncology, 2007, 14, 1896-1903.	1.5	14
31	ERCC1-immunoexpression does not predict platinum-resistance in ovarian cancer. Gynecologic Oncology, 2008, 108, 252-253.	1.4	14
32	Placental site trophoblastic tumor of the mediastinum. Human Pathology, 2005, 36, 581-584.	2.0	13
33	Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 565-574.	2.8	13
34	MPO density in primary cancer biopsies of ovarian carcinoma enhances the indicative value of IL-17 for chemosensitivity. BMC Cancer, 2016, 16, 639.	2.6	13
35	PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 67-76.	2.8	13
36	Correlation and significance of histopathological and clinical features in breast cancer with skin involvement (T4b). Human Pathology, 2006, 37, 264-271.	2.0	12

GAD SINGER

#	Article	IF	CITATIONS
37	Breast cancer with non-inflammatory skin involvement: Current data on an underreported entity and its problematic classification. Breast, 2010, 19, 59-64.	2.2	12
38	Viropathic multinuclear syncytial giant cells in bronchial fluid from a patient with COVID-19. Journal of Clinical Pathology, 2020, 73, 607-608.	2.0	12
39	Non-inflammatory skin involvement in breast cancer, histologically proven but without the clinical and histological T4 category features. Journal of Surgical Oncology, 2007, 95, 291-297.	1.7	11
40	T4 category revision enhances the accuracy and significance of stage III breast cancer. Cancer, 2006, 106, 2569-2575.	4.1	10
41	KIT in Ovarian Carcinoma: Disillusion About a Potential Therapeutic Target. Journal of the National Cancer Institute, 2003, 95, 1009-1010.	6.3	9
42	Histopathologic characteristics of the transitional stage of measles-associated appendicitis: case report and review of the literature. Human Pathology, 2011, 42, 285-290.	2.0	9
43	ALK-negative anaplastic large cell lymphoma arising in the thrombus of an aortic prosthesis preceeded by clonally related lymphomatoid papulosis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 763-767.	2.8	9
44	Correspondence: Reply to â€~Quantitative evaluation of X-ray dark-field images for microcalcification analysis in mammography'. Nature Communications, 2016, 7, 10868.	12.8	8
45	Three-dimensional pathological size assessment in primary breast carcinoma. Breast Cancer Research and Treatment, 2009, 116, 257-262.	2.5	7
46	The Role of New Technologies in the Diagnosis and Surveillance of Non-Muscle Invasive Bladder Carcinoma: A Prospective, Double-Blinded, Monocentric Study of the XPERT© Bladder Cancer Monitor and Narrow Band Imaging© Cystoscopy. Cancers, 2022, 14, 618.	3.7	7
47	Bone Marrow Micrometastases Do Not Impact Disease-Free and Overall Survival in Early Stage Sentinel Lymph Node–Negative Breast Cancer Patients. Annals of Surgical Oncology, 2014, 21, 401-407.	1.5	6
48	Stereotactic Vacuum-Assisted Breast Biopsy in Ductal Carcinoma in situ: Residual Microcalcifications and Intraoperative Findings. Breast Care, 2020, 15, 386-391.	1.4	6
49	Epidemiology in ovarian carcinoma: Lessons from autopsy. Gynecologic Oncology, 2015, 138, 417-420.	1.4	5
50	Can grating interferometry-based mammography discriminate benign from malignant microcalcifications in fresh biopsy samples?. European Journal of Radiology, 2020, 129, 109077.	2.6	5
51	Board examination for anatomical pathology in Switzerland: two intense days to verify professional competence. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 87-92.	2.8	4
52	High ratio of pCXCR4/CXCR4 tumor infiltrating immune cells in primary high grade ovarian cancer is indicative for response to chemotherapy. BMC Cancer, 2022, 22, 376.	2.6	4
53	High Density of CD16+ Tumor-Infiltrating Immune Cells in Recurrent Ovarian Cancer Is Associated with Enhanced Responsiveness to Chemotherapy and Prolonged Overall Survival. Cancers, 2021, 13, 5783.	3.7	3
54	Retroperitoneal displacement of ovary and fallopian tube: a complication of surgical management of incarcerated inguinal hernia in female infants. Journal of Pediatric Surgery, 2007, 42, e33-e35.	1.6	2

GAD SINGER

#	Article	IF	CITATIONS
55	Deciphering the genetic landscape of pulmonary lymphomas. Modern Pathology, 2021, 34, 371-379.	5.5	2
56	Pathology of Breast Tissue Obtained in Minimally Invasive Biopsy Procedures. Recent Results in Cancer Research, 2009, 173, 137-147.	1.8	2
57	Letter to the editors. Surgery, 2002, 131, 473.	1.9	1
58	Impact of Chronic Prostatitis on the PI-RADS Score 3: Proposal for the Addition of a Novel Binary Suffix. Diagnostics, 2021, 11, 623.	2.6	1
59	11 CDX2 Immunostaining in Primary and Secondary Ovarian Carcinomas. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2005, 4, 393-397. –	0.0	0
60	Phase-contrast enhanced mammography: A new diagnostic tool for breast imaging. , 2012, , .		0